Premium
Treatment of paget's disease with intermittent low‐dose infusions of disodium pamidronate (APD)
Author(s) -
Stone Michael D.,
Hawthorne A. Barney,
Kerr David,
Webster Gillian,
Hosking David J.
Publication year - 1990
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650051207
Subject(s) - hydroxyproline , medicine , paget's disease of bone , bone resorption , etidronic acid , bone remodeling , intravenous infusions , alkaline phosphatase , excretion , bone disease , endocrinology , resorption , diphosphonates , osteoporosis , bisphosphonate , disease , chemistry , enzyme , biochemistry
Disodium pamidronate (APD) is a potent inhibitor of bone resorption, with less risk of defective mineralization than earlier bisphosphonates. We assessed the response to six spaced low‐dose intravenous infusions of APD given at intervals of approximately 6 weeks followed by weekly infusions if bone turnover remained abnormal. Three groups of 10 patients were studied, each group receiving infusions of 15, 30, or 45 mg. Hydroxyproline excretion fell by 62% and alkaline phosphatase was reduced by 72%, with no difference between the dose levels. A total of 21 patients (70%) achieved normal levels of bone turnover, indicating that low‐dose infusions of APD are a safe and effective treatment for Paget's disease.